ROSWELL, Ga., May 15, 2025 /PRNewswire/ — BUDS Technology Inc., a leader in AI-powered healthcare solutions, is proud to announce the rebranding of its flagship virtual medical assistant application. Effective immediately, the product formerly known as Nurse Daisy will now operate under the new name AKSSI (pronounced “AX-ee”).
This name change reflects the company’s continued commitment to innovation and clarity in the digital healthcare space. The rebrand aligns with the application’s expanded functionality, advanced artificial intelligence capabilities, and modernized user experience, while also avoiding confusion with similar-sounding names in the marketplace.
AKSSI delivers the same real-time documentation support, intelligent workflow automation, and seamless virtual assistance for healthcare providers. Designed to reduce clinician burnout and improve operational efficiency, AKSSI has become a trusted solution across a growing number of medical settings.
In tandem with the rebrand, BUDS Technology Inc. is also announcing its strategic expansion into the senior living and long-term care markets. This move responds to the urgent need for smarter documentation and staffing support in assisted living communities. The AKSSI platform is now available to hospice agencies and senior living communities across the United States.
For more information, visit www.akssi.com or contact sales@budstechnology.com.
Follow BUDS Technology on LinkedIn for ongoing updates.
Media Contact:
Anna Boisse
Buds Technology Inc.
sales@budstechnology.com
www.budstechnology.com
SOURCE BUDS Technology
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…